The White House criticizes Commissioner Makary for politicized decisions while simultaneously pressuring him to make politically motivated approvals, like for flavored vapes. This creates an untenable conflict where the FDA head is judged for both failing to be independent and for resisting political influence.
Seaport's strategy focuses on molecules with established efficacy, such as allopregnanolone. The core innovation is not discovering new biology but applying its "Glif" platform to solve delivery problems like oral administration and side effects. This model prioritizes technical and commercial enablement over high-risk biological discovery.
Despite political chaos, most FDA work continues. However, companies are experiencing severe inconsistency, with different agency groups offering contradictory advice and major rejections being walked back, as seen with Atara Biotherapeutics. This demonstrates how top-level instability creates unpredictable regulatory hurdles for developers.
Learning from Karuna, Seaport actively combats the high placebo effect in psychiatric trials. Their strategy involves specific design tactics, such as optimizing the frequency of clinician assessments and using a single treatment arm, to minimize both therapeutic interaction and patient expectation bias, which are known drivers of placebo response.
CEO Daphne Zohar uses a platform model to avoid the "sunk cost fallacy" common in single-asset biotechs. Having multiple programs makes the company more willing to reallocate resources from a failing drug to a more promising one, creating better alignment between management decisions and shareholder value.
While analysts widely predicted Eli Lilly's GLP-1 pill would dominate the oral obesity market, early launch data shows Novo Nordisk's Wegovy pill is having the "strongest ever GLP-1 volume launch." This swift market reversal highlights the unpredictability of drug launches, even in highly anticipated categories.